University of Yaounde 1 plans Phase 2 trial of IGOB131 as GLP-1 modulator
The 16-week randomized, placebo-controlled study will track GLP-1 dynamics, DPP-4 activity and inflammatory markers in adults with obesity, with enrollment starting December 2026.
PR
By Priya Raman · Science Reporter
Oct 20 08:00 ETSource: ClinicalTrials.gov
The wire
- 01NCT07884058 is a randomized, double-blind, placebo-controlled Phase 2 trial of standardized Irvingia gabonensis extract IGOB131, dosed daily for 16 weeks with clinic visits every four weeks.
- 02It tests whether a botanical extract can move endogenous GLP-1 and DPP-4 activity, an approach clinicians will hear about from patients seeking non-injectable incretin options.
- 03The trial is not yet recruiting and no sample size or primary endpoint detail is posted; results on adiposity and systemic inflammation remain years away.
From the source
Read at clinicaltrials.govIGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity
NCT07884058 · PHASE2 · NOT YET RECRUITING · Sponsor: University of Yaounde 1 · Conditions: Obesity & Overweight.
Source URL https://clinicaltrials.gov/study/NCT07884058
